Literature DB >> 6732419

The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders.

T H McGlashan.   

Abstract

This report details the long-term course for systematically rediagnosed (and largely chronically ill) patients with schizophrenia (n = 163) and with bipolar (n = 19) and unipolar (n = 44) affective disorders from the Chestnut Lodge, Rockville, Md, follow-up study. Their conditions were assessed and they are described rigorously from multiple outcome perspectives. Except in the realm of symptomatic diathesis, striking differences emerged between these major axis I disorders consonant with Kraepelin's original observations. Roughly two thirds of the schizophrenic patients were functioning marginally or worse at follow-up, compared with one third of the unipolar cohort. The reverse held for better outcomes. Outcome varied little as a function of follow-up interval (time) across all diagnostic categories. Representative case examples serve to place the ratings in meaningful clinical contexts.

Entities:  

Mesh:

Year:  1984        PMID: 6732419     DOI: 10.1001/archpsyc.1984.01790170060007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

Review 1.  Improving outcome in schizophrenia: the case for early intervention.

Authors:  A K Malla; R M Norman; L P Voruganti
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

Review 2.  Recovery in schizophrenia: reality or mere slogan.

Authors:  Natalie B Slopen; Patrick W Corrigan
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

4.  Depression in the long-term course of schizophrenia.

Authors:  Wolfram an der Heiden; Regina Könnecke; Kurt Maurer; Daniel Ropeter; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  Duration of the psychosis prodrome.

Authors:  Albert R Powers; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-02       Impact factor: 4.939

Review 7.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

8.  Training professionals to work with families of chronic patients.

Authors:  H P Lefley
Journal:  Community Ment Health J       Date:  1988

Review 9.  Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage.

Authors:  Peter Kochunov; L Elliot Hong
Journal:  Schizophr Bull       Date:  2014-05-27       Impact factor: 9.306

10.  Smaller than expected cognitive deficits in schizophrenia patients from the population-representative ABC catchment cohort.

Authors:  Leonhard Lennertz; Wolfram An der Heiden; Regina Kronacher; Svenja Schulze-Rauschenbach; Wolfgang Maier; Heinz Häfner; Michael Wagner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-02       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.